Cytokinetics Inc
CYTK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001061983
In the last 90 days, Cytokinetics Inc insiders filed 0 open-market purchases and 18 sales; 481 institutions reported holding it in 13F filings for Q2 2026, worth $13.7B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $15.4M in total
- 18
- 13F holdersQ2 2026, +46 vs. previous quarter
- 481
- 13F valueReported value at the end of Q2 2026
- $13.7B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CYTK, Q2 2026
No superinvestor reported holding CYTK at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cytokinetics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 (view filing)6:14 PM ET | Sep 22 | Same day | Malik Fady IbrahamEVP Research & Development | SSale | −3.50K | $68.29 | −$239.0K | −2.2%153.9K after | 10b5-1 |
| Sep 15, 2026 (view filing)5:23 PM ET | Sep 15 | Same day | Landry Robert EDirector | SSale | −1.00K | $72.13 | −$72.1K | −10.9%8.18K after | 10b5-1 |
| Sep 15, 2026 (view filing)5:20 PM ET | Sep 14 | 1 day | Blum Robert IPresident & CEO | SSale | −7.50K | $73.44 | −$550.8K | −1.9%377.8K after | 10b5-1 |
| Sep 15, 2026 (view filing)5:20 PM ET | Sep 15 | Same day | Blum Robert IPresident & CEO | SSale | −97.9K | $69.33 | −$6.79M | −100.0%0 after | 10b5-1 |
| Sep 11, 2026 (view filing)7:12 PM ET | Sep 11 | Same day | Landry Robert EDirector | SSale | −1.00K | $74.66 | −$74.7K | −9.8%9.18K after | 10b5-1 |
| Sep 8, 2026 (view filing)4:38 PM ET | Sep 8 | Same day | Malik Fady IbrahamEVP Research & Development | SSale | −3.50K | $75.46 | −$264.1K | −2.2%153.9K after | 10b5-1 |
| Sep 1, 2026 (view filing)4:51 PM ET | Sep 1 | Same day | Parshall B LynneDirector | SSale | −5.00K | $71.48 | −$357.4K | −31.7%10.8K after | 10b5-1 |
| Aug 31, 2026 (view filing)4:57 PM ET | Aug 31 | Same day | Callos AndrewEVP, Chief Commercial Officer | SSale | −10.0K | $70.24 | −$702.4K | −14.6%58.6K after | 10b5-1 |
| Aug 31, 2026 (view filing)4:55 PM ET | Aug 31 | Same day | Blum Robert IPresident & CEO | SSale | −7.50K | $70.24 | −$526.8K | −1.9%377.8K after | 10b5-1 |
| Aug 18, 2026 (view filing)4:38 PM ET | Aug 18 | Same day | Malik Fady IbrahamEVP Research & Development | SSale | −3.50K | $75.82 | −$265.4K | −2.2%153.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Cytokinetics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,094,362 | $1.71B | 0.03% | +3,546,351+21.4% | Added |
| T. Rowe Price Investment Management, Inc. | 18,718,498 | $1.59B | 1.05% | +1,194,658+6.8% | Added |
| Wellington Management Group LLP | 6,931,770 | $590.5M | 0.10% | −1,077,719−13.5% | Reduced |
| Vanguard Portfolio Management LLC | 6,711,799 | $571.8M | 0.03% | +868,017+14.9% | Added |
| State Street Corp | 6,494,233 | $553.2M | 0.02% | +749,040+13.0% | Added |
| Vanguard Capital Management LLC | 6,117,515 | $521.2M | 0.01% | +628,881+11.5% | Added |
| FMR LLC | 5,031,782 | $428.7M | 0.02% | −5,691,358−53.1% | Reduced |
| Avoro Capital Advisors LLC | 4,999,999 | $425.9M | 3.82% | +1,666,666+50.0% | Added |
| Bank of America Corp | 4,635,709 | $394.9M | 0.03% | +1,510,273+48.3% | Added |
| Geode Capital Management, LLC | 3,712,501 | $316.3M | 0.02% | +497,086+15.5% | Added |